MDGL Madrigal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDGL

Price (delayed)

$493.7

Market cap

$11.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.76

Enterprise value

$11.5B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 38

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The EPS has increased by 26% YoY
The revenue has increased by 18% since the previous quarter
The company's net income rose by 21% YoY but it fell by 7% QoQ
The debt has surged by 190% year-on-year
The company's quick ratio fell by 45% YoY and by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.madrigalpharma.com

Key stats

What are the main financial stats of MDGL

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
1.14%
1 week
-4.31%
1 month
-4.81%
1 year
76.75%
YTD
-15.22%
QTD
-5.69%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$1.13B
Gross profit
$1.05B
Operating income
-$313.55M
Net income
-$309.44M
Gross margin
93.1%
Net margin
-27.3%
Madrigal Pharmaceuticals's operating margin has soared by 79% YoY and by 12% from the previous quarter
The net margin has surged by 78% year-on-year and by 9% since the previous quarter
MDGL's operating income is up by 26% YoY but it is down by 4.5% QoQ
The company's net income rose by 21% YoY but it fell by 7% QoQ

Price vs fundamentals

How does MDGL's price correlate with its fundamentals

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
20.84
P/S
12.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.15
The EPS has increased by 26% YoY
The equity is down by 24% year-on-year and by 10% since the previous quarter
The stock's price to book (P/B) is 18% more than its last 4 quarters average of 17.5 but 15% less than its 5-year quarterly average of 24.3
The revenue has increased by 18% since the previous quarter
The P/S is 7% lower than the last 4 quarters average of 13.5

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
The ROS has soared by 79% YoY and by 10% from the previous quarter
Madrigal Pharmaceuticals's ROIC has increased by 42% YoY
MDGL's return on assets is up by 32% year-on-year but it is down by 2% since the previous quarter
The ROE has contracted by 15% from the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets is 79% more than its total liabilities
Madrigal Pharmaceuticals's total liabilities has soared by 139% YoY and by 4.1% from the previous quarter
The company's quick ratio fell by 45% YoY and by 18% QoQ
The debt is 36% smaller than the equity
The debt has surged by 190% year-on-year
The equity is down by 24% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.